Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.59 |
| ▸ | BACE1 | P56817 | 5/20 | 0.59 |
| ▸ | BCHE | P06276 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278631 | 0.81 | ACHE (0.62) | ACHEBACE1BCHESIGMAR1DPP7 | |
| Hydrochloric Acid SCHEMBL9785794 | 0.80 | ACHE (0.60) | ACHEBACE1BCHESIGMAR1DPP7 | |
| SCHEMBL6503006 | 0.80 | CCR8 (0.62) | ALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL9785708 | 0.79 | ACHE (0.59) | ACHEBACE1BCHESIGMAR1DPP7 | |
| SCHEMBL5271846 | 0.78 | GAA (0.59) | ACHEBACE1BCHESIGMAR1KMT2A | |
| SCHEMBL5094770 | 0.78 | ACHE (0.57) | ACHEBACE1BCHESIGMAR1DPP7 | |
| SCHEMBL9730843 | 0.77 | ACHE (0.54) | ACHEBACE1BCHESIGMAR1DPP7 | |
| SCHEMBL2840739 | 0.77 | ACHE (0.70) | ACHEBACE1BCHESIGMAR1DRD4 | |
| SCHEMBL4690024 | 0.77 | ACHE (0.69) | ACHEBACE1BCHESIGMAR1DPP7 | |
| SCHEMBL6749008 | 0.76 | HTT (0.65) | ACHEBACE1BCHESIGMAR1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | disclosed |
| US-7776315-B2 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20040151770-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-05 | — | — | US | disclosed |
| US-6747044-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIULCER AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-06-08 | — | — | US | disclosed |
| US-6696042-B2 | INHALATION AEROSOL COMPRISING TIOTROPIUM SALT AND PROPELLANT GAS; RESPIRATORY SYSTEM DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-02-24 | — | — | US | disclosed |
| EP-1370293-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICS AND ON NK1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-13 | — | — | US | disclosed |
| US-6620438-B2 | Arylglycinamide derivatives | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-16 | — | — | US | disclosed |
| EP-1328516-A1 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20030100565-A1 | Method for the treatment or prevention of atopic dermatitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-05-29 | — | — | US | disclosed |
| WO-2003026658-A1 | METHOD FOR THE TREATMENT OR PREVENTION OF ATOPIC DERMATITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-04-03 | — | — | WO | disclosed |
| EP-1295599-A1 | Method for the treatment of prevention of atopic dermatitis | Boehringer Ingelheim International GmbH (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-20020169181-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-20020147219-A1 | Neurokinin antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-10 | — | — | US | disclosed |
| WO-2002069944-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICS AND ON NK1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002032865-A1 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | ACHE 20/4885BACE1 1287/4885BCHE 147/4885 |
| US-20040151770-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | TACR2, CHRM3, TACR1 | ACHE 129/4885BACE1 1150/4885BCHE 221/4885 |
| US-20020147219-A1 | Neurokinin antagonists | TACR2, TACR1, TAC3 | ACHE 1524/4885BACE1 1597/4885BCHE 1492/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | ACHE 16/4885BACE1 2008/4885BCHE 249/4885 |
| US-20020169181-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | TACR2, CHRM3, TACR1 | ACHE 129/4885BACE1 1150/4885BCHE 221/4885 |
| US-20030100565-A1 | Method for the treatment or prevention of atopic dermatitis | TACR1, BDKRB1, CPA3 | ACHE 1527/4885BACE1 224/4885BCHE 1046/4885 |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | TACR2, CHRM3, TACR1 | ACHE 129/4885BACE1 1150/4885BCHE 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.